Boardroom Alpha
Boardroom Alpha
TMO · Current Report (Form 8-K) · Filed January 12, 2026

Thermo Fisher Scientific Inc — Current Report (Form 8-K)

Form
8-K
Filed
January 12, 2026
Period
Jan 12, 2026
Ticker
TMO
Accession
0001140361-26-000871
Boardroom Alpha · Filing insights

Two Thermo Fisher executives will depart; leadership changes set March 1, 2026, with Casper as CEO and Pettiti as President/COO.

About Thermo Fisher Scientific Inc
Market cap
$179.2B
1Y TSR
+14.6%
3Y TSR
−3.7%
Board grade
B-
Sector
Healthcare
CEO
Marc N Casper
Last annual meeting: May 20, 2026 · View full Thermo Fisher Scientific Inc profile →

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2026

THERMO FISHER SCIENTIFIC INC.
(Exact name of Registrant as specified in its Charter)

Delaware
1-8002
04-2209186
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)

168 Third Avenue
Waltham, Massachusetts 02451
(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (781) 622-1000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class
 
Trading Symbol(s)
 
Name of each exchange on which registered
Common Stock, $1.00 par value
 
TMO
 
New York Stock Exchange
3.200% Notes due 2026
 
 TMO 26B
 
New York Stock Exchange
1.400% Notes due 2026
 
 TMO 26A
 
New York Stock Exchange
1.450% Notes due 2027
 
TMO 27
 
New York Stock Exchange
1.750% Notes due 2027
 
TMO 27B
 
New York Stock Exchange
Floating Rate Senior Notes due 2027
 
TMO 27D
 
New York Stock Exchange
0.500% Notes due 2028
 
TMO 28A
 
New York Stock Exchange
1.375% Notes due 2028
 
TMO 28
 
New York Stock Exchange
1.950% Notes due 2029
 
TMO 29
 
New York Stock Exchange
0.875% Notes due 2031
 
TMO 31
 
New York Stock Exchange
2.375% Notes due 2032
 
TMO 32
 
New York Stock Exchange
3.650% Notes due 2034
 
TMO 34
 
New York Stock Exchange
3.628% Senior Notes due 2035
 
TMO 35A
 
New York Stock Exchange
2.875% Notes due 2037
 
TMO 37
 
New York Stock Exchange
1.500% Notes due 2039
 
TMO 39
 
New York Stock Exchange
1.875% Notes due 2049
 
TMO 49
 
New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐



Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Each of Michel Lagarde and Frederick M. Lowery have notified Thermo Fisher Scientific Inc. (the “Company”) of their decisions to leave the Company to pursue other opportunities. Mr. Lagarde, who has served as Executive Vice President and Chief Operating Officer of the Company since 2021 will depart on March 31, 2026, and Mr. Lowery, who has served as an Executive Vice President of the Company since 2024 will depart on February 28, 2026.

Effective March 1, 2026, Thermo Fisher Scientific will update its organizational structure and leadership team. Marc N. Casper will become Chairman and Chief Executive Officer. Gianluca Pettiti, currently an Executive Vice President, will be promoted and transition to the role of President and Chief Operating Officer. Also, as of that date, Michael Shafer, currently an Executive Vice President, will be promoted to an expanded role and will report directly to the Chief Executive Officer.

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
THERMO FISHER SCIENTIFIC INC.
       
Date: 
 January 12, 2026
By:
/s/ Thomas B. Shropshire
     
Thomas B. Shropshire
     
Senior Vice President and General Counsel


3

From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Thermo Fisher Scientific Inc (TMO)

Reference

Frequently asked questions

When did Thermo Fisher Scientific Inc file this 8-K?
Thermo Fisher Scientific Inc (TMO) filed this Current Report (Form 8-K) with the SEC on January 12, 2026. The accession number assigned by EDGAR is 0001140361-26-000871.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Two Thermo Fisher executives will depart; leadership changes set March 1, 2026, with Casper as CEO and Pettiti as President/COO. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Thermo Fisher Scientific Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Thermo Fisher Scientific Inc has filed under CIK 97745, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer